Explore chapters and articles related to this topic
A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children
Published in Expert Review of Neurotherapeutics, 2022
Jordan L. Clay, Nathan B. Fountain
Due to the alkalinity of the parenteral formulation of PHT, there is risk of local phlebitis and pain with injection [34–36]. If there is extravasation into surrounding tissue, there is risk of edema, discoloration, and possible necrosis, known as the ‘purple glove syndrome’ (PGS) which can lead to amputations. A recent review of all cases of PGS noted an incidence of 1–7%, with eight amputations reported [49]. These adverse effects also limit PHT’s ability to be administered via IM route. In contrast, IV and IM formulations of fPHT have been shown to have a significantly decreased incidence of soft tissue adverse effects when compared head-to-head with PHT in adults [27,37,38,46,49,50].